<DOC>
	<DOCNO>NCT02965911</DOCNO>
	<brief_summary>The purpose protocol conduct trial select population patient PBC base incomplete biochemical response 12 month UDCA therapy .</brief_summary>
	<brief_title>Efficacy Safety Fenofibrate Combined With UDCA PBC Patients With Incomplete Biochemical Response UDCA</brief_title>
	<detailed_description>Primary biliary cholangitis chronic cholestatic liver disease , ursodeoxycholic acid ( UDCA ) drug approve treatment PBC . Although UDCA improve clinical outcome patient PBC , 40 % PBC patient show incomplete biochemical response treatment , accordingly significantly increase risk develop liver transplantation death . Therefor urgently need good therapy patient . The development new treatment therefore need . The Fenofibrate candidate , substantial body circumstantial evidence support Fenofibrate well tolerate improve biochemical response PBC patient incompleted response UDCA . The purpose protocol conduct trial select population patient PBC base incomplete biochemical response 12 month UDCA therapy .</detailed_description>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1 . PBC Patient , previous treatment UDCA 1315 mg/kg/day least 1 year , show incomplete biochemical response ; 2 . Patients show incomplete biochemical response UDCA define : ALP &gt; 3ULN , AST &gt; 2N , total bilirubin &gt; 17 µmol/l ≥ 12 month UDCA dose 13 15 mg/kg/day . 3 , sign informed consent careful review information study detail . 1 . Hypersensitivity fenofibrate 2 . Administration follow drug time 3 month prior screen study : methotrexate , colchicine , azathioprine , systemic steroid . 3 . Decompensation PBC , recurrent variceal hemorrhage , uncontrolled encephalopathy refractory ascites 4 . Anticipated need liver transplantation within one year 5 . Coexisting liver disease acute chronic viral hepatitis , alcoholic liver disease , choledocholithiasis , autoimmune hepatitis , biopsyproven nonalcoholic fatty liver disease , Wilson 's disease hemochromatosis 6 . Acute chronic renal failure 7 . Known history cholecystitis intact gallbladder 8 . Pregnant nursing woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>UDCA , Fenofibrate</keyword>
</DOC>